In subgroup III, CDK4 amplification and PRKDC amplification jointly promoted increased CDK4 protein expression and kinase activity in melanoma patients, accelerating the proliferation rate of melanoma and leading to poor prognosis. Here, PRKDC is linked to melanoma.